Breaking News Instant updates and real-time market news.

AVGO

Broadcom

$218.78

1.86 (0.86%)

, OBSV

ObsEva

$14.90

0.53 (3.69%)

10:16
08/07/18
08/07
10:16
08/07/18
10:16

On The Fly: Top five analyst initiations

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Broadcom (AVGO) reinstated with an Overweight at Barclays. 2. ObsEva (OBSV) initiated with an Outperform at Wedbush. 3. Deciphera (DCPH) initiated with a Buy at Canaccord. 4. Alliance Data (ADS) assumed with a Buy at Jefferies. 5. Hermes (HESAY) initiated with an Equal Weight at Morgan Stanley. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

AVGO

Broadcom

$218.78

1.86 (0.86%)

OBSV

ObsEva

$14.90

0.53 (3.69%)

DCPH

Deciphera

$39.06

2.95 (8.17%)

ADS

Alliance Data

$228.29

0.35 (0.15%)

HESAY

Hermes

$0.00

(0.00%)

  • 08

    Aug

  • 08

    Aug

  • 14

    Aug

  • 04

    Sep

  • 12

    Sep

  • 06

    Nov

AVGO Broadcom
$218.78

1.86 (0.86%)

08/01/18
KEYB
08/01/18
NO CHANGE
KEYB
Apple's results positive for supply-chain companies, says KeyBanc
KeyBanc analyst John Vinh views Apple's (AAPL) "solid" results as positive for the company's supply-chain companies Broadcom (AVGO), Cirrus Logic (CRUS), Qorvo (QRVO), Skyworks (SWKS), and Synaptics (SYNA), as results indicate that demand has finally stabilized ahead of the new iPhone ramp. Additionally, lean channel commentary gets him incrementally more positive ahead of the new iPhone ramp, he contends. Vinh's favorite Apple supply-chain names are Broadcom, Qorvo, Skyworks, and Synaptics.
08/01/18
OPCO
08/01/18
NO CHANGE
OPCO
iPhone ASP, guide imply iPX partially offsetting longer replacement cycle, says Oppenheimer
Oppenheimer analyst Rick Schafer believes June Apple's (AAPL) iPhone ASP and the guide imply broader penetration of iPhone X partially offsetting a longer replacement cycle. Within the Apple supply chain, the analyst continues to prefer content increase stories, and consistent track records of execution, helping insulate from demand softness. His top picks in the Apple supply chain are Broadcom (AVGO) and Skyworks (SWKS). Schafer remains sidelined on Cirrus Logic (CRUS) given lack of a near-term content expansion story, as well as on Qorvo (QRVO), as much of the benefit from the expected mid/high-band PAD win in the coming iPhone refresh appears modeled into expectations.
08/06/18
MSCO
08/06/18
NO CHANGE
MSCO
Boeing, Tesla, Nvidia make Morgan Stanley 'key man risk' list
Morgan Stanley equity strategist Mark Savino noted that about 12% of CEO jobs among S&P 500 companies turned over in 2017, noting that this was the highest level of CEO departures since before the financial crisis. The 59 stocks of S&P 500 companies that had CEOs depart in 2017 underperformed the market by 11% over the next 12 months, or since the departure for instances that were less than 12 months ago, noted Savino. In cooperation with the firm's U.S. analysts, Savino and his team identified the companies in each sector they believe face the greatest level of "key man risk," which includes: Boeing (BA), Tesla (TSLA), ADT Inc. (ADT), Moody's (MCO), TransUnion (TRU), Arista Networks (ANET), Church & Dwight (CHD), Coca-Cola (KO), Monster Beverage (MNST), Coupa Software (COUP), Salesforce (CRM), FireEye (FEYE), MongoDB (MDB), Microsoft (MSFT), New Relic (NEWR), XPO Logistics (XPO), Hilton (HLT), Las Vegas Sands (LVS), Best Buy (BBY), Ulta (ULTA), Aflac (AFL), Athene Holding (ATH), Lincoln National (LNC), Arthur J. Gallagher (AJG), Chubb (CB), Amazon.com (AMZN), Activision Blizzard (ATVI), Facebook (FB), Alphabet (GOOGL), Apple (AAPL), Terex (TEX), Cleveland-Cliffs (CLF), Freeport McMoRan (FCX), FleetCor (FLT), Global Payments (GPN), Square (SQ), Jazz Pharmaceuticals (JAZZ), Cheesecake Factory (CAKE), Broadcom (AVGO), Nvidia (NVDA), Chegg (CHGG), DXC Technology (DXC), Medidata (MDSO), Pluralsight (PS), RealPage (RP), Shopify (SHOP) and T-Mobile (TMUS).
08/07/18
LEHM
08/07/18
INITIATION
Target $265
LEHM
Overweight
Broadcom reinstated with an Overweight at Barclays
Barclays analyst Blayne Curtis reinstated coverage of Broadcom with an Overweight rating and $265 price target.
OBSV ObsEva
$14.90

0.53 (3.69%)

08/07/18
WEDB
08/07/18
INITIATION
Target $34
WEDB
Outperform
ObsEva initiated with an Outperform at Wedbush
Wedbush analyst Liana Moussatos started ObsEva with an Outperform rating and $34 price target. The analyst projects initial approvals/launches in the U.S. and EU in 2021-2022, full-year profitability in 2024 and the potential to reach over $1B in total revenues in 2026.
08/06/18
WEDB
08/06/18
INITIATION
WEDB
Outperform
ObsEva initiated with an Outperform at Wedbush
07/19/18
FBCO
07/19/18
INITIATION
Target $24
FBCO
Outperform
ObsEva initiated with an Outperform at Credit Suisse
Credit Suisse initiated ObsEva with an Outperform and $24 price target.
06/19/18
BMOC
06/19/18
NO CHANGE
Target $31
BMOC
Outperform
ObsEva price target raised to $31 from $23 at BMO Capital
BMO Capital analyst Peter Lawson raised his price target on ObsEva to $31 following the positive OBE2109 EDELWEISS data in endometriosis, saying the results "confirm comparable high dose efficacy to leader Elagolix" with better balanced pain benefit. Lawson adds that the 5-month bone data expected in Q4 of this year will further support the OBE2109 preferable profile, leading to the initiation of a Phase 3 endometriosis study in Q1 of 2019. The analyst is also positive on additional upside coming from the Nolasiban live birth rate data and OBE022 phase 2 read-out in Q4, keeping his Outperform rating on ObsEva.
DCPH Deciphera
$39.06

2.95 (8.17%)

06/19/18
JMPS
06/19/18
NO CHANGE
Target $65
JMPS
Outperform
Deciphera price target raised to $65 from $38 at JMP Securities
JMP Securities analyst Konstantinos Aprilakis said he believes Deciphera's recently reported updated data from the ongoing Phase I study of DCC-2618 "strongly" supports the company's decision to initiate a pivotal trial in second-line GIST and bolsters his expectations that 2618 will prove superior to currently available therapies in earlier-line use. Ahead of what he expects to be the presentation of more detailed response data in earlier lines of GIST, as well as durability of response and median PFS results, later this year, Aprilakis raised his price target on Deciphera shares to $65 and keeps an Outperform rating on the shares.
07/05/18
RHCO
07/05/18
INITIATION
Target $60
RHCO
Buy
Deciphera initiated with a Buy at SunTrust
SunTrust analyst Peter Lawson initiated Deciphera (DCPH) with a Buy rating and a price target of $60, citing the company's differentiated position of developing kinase inhibitors that can hit multiple mutations, potentially better controlling cancer. Given its wholly owned pipeline of 3 clinical drugs, the lead of which is targeting Gastrointestinal stromal tumor in two phase 3 trials by the second half of this year, the analyst recommends that investors acquire shares ahead of those readouts. Lawson further states that other kinase targeting peer companies such as Loxo Oncology (LOXO), Blueprint Medicines (BPMC), and Mirati Therapeutics (MRTX) also point to significant upside amid clinical validation progress.
07/05/18
07/05/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Deciphera (DCPH) initiated with a Buy at SunTrust. 2. EQT Corporation (EQT) initiated with a Hold at TD Securities. 3. Pioneer Natural (PXD) initiated with a Buy at TD Securities. 4. Veoneer (VNE) initiated with an Overweight at Barclays. 5. Valeritas (VLRX) initiated with an Outperform at Oppenheimer. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/07/18
ADAM
08/07/18
INITIATION
Target $55
ADAM
Buy
Deciphera initiated with a Buy at Canaccord
Canaccord analyst Arlinda Lee initiated Deciphera with a Buy rating as she believes its Kinase switch control platform is attractive since it has generated three wholly owned, oral drug candidates that inhibit activation of oncologic driver kinases and can generate additional therapies. Lee has a $55 price target on Deciphera shares.
ADS Alliance Data
$228.29

0.35 (0.15%)

08/07/18
JEFF
08/07/18
INITIATION
Target $280
JEFF
Buy
Alliance Data assumed with a Buy at Jefferies
Jefferies analyst Surinder Thind assumed coverage of Alliance Data with a Buy rating and $280 price target. The company's long-term business fundamentals are intact but are being masked by a number of transitory events, Thind tells investors in a research note. He expects the stock's forward price-to-earnings multiple to re-rate from 9 times currently to 11 times as the headwinds dissipate.
07/18/18
JPMS
07/18/18
NO CHANGE
Target $264
JPMS
Neutral
JPMorgan 'incrementally positive' on Alliance Data into earnigns
JPMorgan analyst Reginald Smith keeps a Neutral rating on Alliance Data but is "incrementally positive" on the shares into the company's Q2 results on July 19. The analyst raised his estimates and sees upside to management's prior Q2 outlook given commentary at investor conferences last month. He cites Alliance Data's relative valuation and potential for improved credit metrics for his incrementally positive stance. Smith, however, awaits "more consistency before getting more constructive on the name."
07/17/18
WOLF
07/17/18
INITIATION
Target $290
WOLF
Outperform
Alliance Data initiated with an Outperform at Wolfe Research
Wolfe Research analyst Darrin Peller initiated Alliance Data with an Outperform and $290 price target.
07/17/18
SPHN
07/17/18
NO CHANGE
Target $301
SPHN
Overweight
Alliance Data has 'goalpost' moved again by disappointing June, says Stephens
Stephens analyst Vincent Caintic said he had thought Alliance Data's delinquencies would materially improve in June, but he is now hesitant to model improving delinquencies at September given that both delinquencies and net losses were worse than guidance recently provided at industry conferences and the firm's roadshow. The analyst, who thinks the "disappointing" June has moved the "goalpost" again for Alliance Data, keeps an Overweight rating on the stock but trimmed his price target to $301 from $304.
HESAY Hermes
$0.00

(0.00%)

03/28/18
GSCO
03/28/18
INITIATION
GSCO
Neutral
Hermes initiated with a Neutral at Goldman Sachs
Goldman Sachs analyst Louise Singlehurst started Hermes with a Neutral rating and EUR 474.5 price target.
08/07/18
MSCO
08/07/18
INITIATION
MSCO
Equal Weight
Hermes initiated with an Equal Weight at Morgan Stanley
Morgan Stanley Edouard Aubin initiated Hermes with an Equal Weight rating and EUR490 price target, stating that he believes its valuation premium versus the luxury goods sector is largely justified by its sales predictability and "industry leading" and expanding ROIC.

TODAY'S FREE FLY STORIES

SBUX

Starbucks

$66.80

0.7 (1.06%)

13:56
12/13/18
12/13
13:56
12/13/18
13:56
Hot Stocks
Breaking Hot Stocks news story on Starbucks »

Starbucks sees growing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 14

    Dec

SBUX

Starbucks

$66.81

0.71 (1.07%)

13:56
12/13/18
12/13
13:56
12/13/18
13:56
Hot Stocks
Breaking Hot Stocks news story on Starbucks »

Starbucks sees U.S.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 14

    Dec

13:55
12/13/18
12/13
13:55
12/13/18
13:55
General news
U.S. equities remain mixed after rotating lower »

U.S. equities remain…

CSTM

Constellium

$8.39

-0.02 (-0.24%)

13:51
12/13/18
12/13
13:51
12/13/18
13:51
Hot Stocks
Constellium trading higher by 1.67% during 2018 Analyst Day presentation »

Constellium management is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 17

    Dec

  • 18

    Dec

SBUX

Starbucks

$66.67

0.57 (0.86%)

13:45
12/13/18
12/13
13:45
12/13/18
13:45
Hot Stocks
Starbucks CEO says customer behaviors shifting rapidly, company must adapt »

Starbucks CEO Kevin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 14

    Dec

ADBE

Adobe

$245.82

0.38 (0.15%)

, COST

Costco

$225.99

-1.83 (-0.80%)

13:42
12/13/18
12/13
13:42
12/13/18
13:42
Earnings
Notable companies reporting after market close »

Notable companies…

ADBE

Adobe

$245.82

0.38 (0.15%)

COST

Costco

$225.99

-1.83 (-0.80%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 13

    Dec

SPY

SPDR S&P 500 ETF Trust

$264.81

-0.72 (-0.27%)

13:40
12/13/18
12/13
13:40
12/13/18
13:40
Options
Four-day hedge opened in SPYders »

Four-day hedge opened in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WYNN

Wynn Resorts

$109.16

-0.31 (-0.28%)

, LVS

Las Vegas Sands

$55.16

-0.3 (-0.54%)

13:36
12/13/18
12/13
13:36
12/13/18
13:36
Periodicals
Breaking Periodicals news story on Wynn Resorts, Las Vegas Sands »

Chanos shorting Wynn…

WYNN

Wynn Resorts

$109.16

-0.31 (-0.28%)

LVS

Las Vegas Sands

$55.16

-0.3 (-0.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JD

JD.com

$22.72

0.82 (3.74%)

13:30
12/13/18
12/13
13:30
12/13/18
13:30
Options
Call spreads in JD as shares gain 3.5% and a bullish position is adjusted »

Call spreads in JD as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HIL

Hill International

$2.98

-0.11 (-3.56%)

13:29
12/13/18
12/13
13:29
12/13/18
13:29
Hot Stocks
Hill International selected by the ERBD to provide railway supervision services »

Hill International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LBAI

Lakeland Bancorp

$14.83

-0.27 (-1.79%)

13:27
12/13/18
12/13
13:27
12/13/18
13:27
Hot Stocks
Highlands Bancorp investors approve merger with Lakeland Bancorp »

Lakeland Bancorp and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NLSN

Nielsen

$25.70

-0.36 (-1.38%)

, BX

Blackstone

$30.22

-0.28 (-0.92%)

13:24
12/13/18
12/13
13:24
12/13/18
13:24
Periodicals
Nielsen to hold talks with potential buyers in January, CNBC says »

Nielsen (NLSN) intends to…

NLSN

Nielsen

$25.70

-0.36 (-1.38%)

BX

Blackstone

$30.22

-0.28 (-0.92%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGT

Target

$66.44

-1.36 (-2.01%)

, WMT

Walmart

$92.78

-0.34 (-0.37%)

13:23
12/13/18
12/13
13:23
12/13/18
13:23
Hot Stocks
New York AG sues Target, Walmart over lead-contaminated toy sales »

New York Attorney General…

TGT

Target

$66.44

-1.36 (-2.01%)

WMT

Walmart

$92.78

-0.34 (-0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

HIIQ

Health Insurance Innovations

$29.08

-0.985 (-3.28%)

13:21
12/13/18
12/13
13:21
12/13/18
13:21
Hot Stocks
Breaking Hot Stocks news story on Health Insurance Innovations »

Health Insurance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

MET

MetLife

$39.30

-0.27 (-0.68%)

13:20
12/13/18
12/13
13:20
12/13/18
13:20
Options
Call buyer in MetLife lays out $57K for one-day trade »

Call buyer in MetLife…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

HIIQ

Health Insurance Innovations

$29.08

-0.985 (-3.28%)

13:20
12/13/18
12/13
13:20
12/13/18
13:20
Hot Stocks
Breaking Hot Stocks news story on Health Insurance Innovations »

Health Insurance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
12/13/18
12/13
13:17
12/13/18
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
12/13/18
12/13
13:16
12/13/18
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MELI

MercadoLibre

$338.18

-23.4 (-6.47%)

13:15
12/13/18
12/13
13:15
12/13/18
13:15
Options
MercadoLibre put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:15
12/13/18
12/13
13:15
12/13/18
13:15
General news
Treasury's $16 B 30-year reopening was ok, but nothing special »

Treasury's $16 B…

13:15
12/13/18
12/13
13:15
12/13/18
13:15
General news
Treasury Action: yields tipped lower from highs »

Treasury Action: yields…

FB

Facebook

$143.95

-0.31 (-0.21%)

13:10
12/13/18
12/13
13:10
12/13/18
13:10
Hot Stocks
Facebook says Guardian did not utilize all information on fact-checking program »

Facebook Head of News…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:06
12/13/18
12/13
13:06
12/13/18
13:06
General news
30-Yr Bond Auction Coupon Rate data reported »

30-Yr Bond Auction Coupon…

13:06
12/13/18
12/13
13:06
12/13/18
13:06
General news
30-Yr Bond Auction Total Amount data reported »

30-Yr Bond Auction Total…

13:05
12/13/18
12/13
13:05
12/13/18
13:05
General news
FX Action: USD-CAD »

FX Action: USD-CAD…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.